Photodynamic therapy alone versus combined with intravitreal bevacizumab for neovascular age-related macular degeneration without polypoidal choroidal vasculopathy in Japanese patients

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 248, Issue 7, 2010, Pages 931-936

  Hara, Ryuhei ^a   Kawaji, Takahiro ^a   Inomata, Yasuya ^a   Tahara, Jin ^a   Sagara, Nina ^a   Fukushima, Mikiko ^a   Tanihara, Hidenobu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Age related macular degeneration; Bevacizumab; Combined therapy; Japanese patients; Photodynamic therapy; Polypoidal choroidal vasculopathy

Indexed keywords

BEVACIZUMAB; VERTEPORFIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SAFETY; ENDOPHTHALMITIS; EYE INFLAMMATION; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; JAPANESE; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; SYSTEMIC DISEASE; TRAUMATIC CATARACT; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ASIAN CONTINENTAL ANCESTRY GROUP; CHOROID; CLINICAL TRIALS AS TOPIC; FEMALE; FOLLOW-UP STUDIES; FOVEA CENTRALIS; HUMANS; INJECTIONS, INTRAOCULAR; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 77955659292     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-010-1343-8     Document Type: Article

References (36)

1. Treatment ofAge-RelatedMacularDegenerationwith Photodynamic Therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol 117:1329-1345
2. Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 119:198-207
3. Treatment ofAge-RelatedMacularDegenerationwith Photodynamic Therapy Study Group (2002) Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch Ophthalmol 120:1443-1454
4. Japanese Age-Related Macular Degeneration Trial Study Group (2003) Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 136:1049-1061
5. Yannuzzi LA, Wong DW, Sforzolini BS, Goldbaum M, Tang KC, Spaide RF, Freund KB, Slakter JS, Guyer DR, Sorenson JA, Fisher Y, Maberley D, Orlock DA (1999) Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol 117:1503-1510
6. Ciardella AP, Donsoff IM, Huang SJ, Costa DL, Yannuzzi LA (2004) Polypoidal choroidal vasculopathy. Surv Ophthalmol 49:25-37
7. Sho K, Takahashi K, Yamada H, Wada M, Nagai Y, Otsuji T, Nishikawa M, Mitsuma Y, Yamazaki Y, Matsumura M, Uyama M (2003) Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol 121:1392-1396
8. Obata R, Yanagi Y, Kami J, Takahashi H, Inoue Y, Tamaki Y (2006) Polypoidal choroidal vasculopathy and retinochoroidal anastomosis in Japanese patients eligible for photodynamic therapy for exudative age-related macular degeneration. Jpn J Ophthalmol 50:354-360
9. Spaide RF, Donsoff I, Lam DL, Yannuzzi LA, Jampol LM, Slakter J, Sorenson J, Freund KB (2002) Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina 22:529-535
10. Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, Wong TH (2004) Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy. One-year results of a prospective case series Ophthalmology 111:1576-1584
11. Ogino T, Takeda M, Imaizumi H, Okushiba U (2007) Photodynamic therapy for age-related macular degeneration in Japanese patients: results after one year. Jpn J Ophthalmol 51:210-215
12. Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, Ikuno Y, Tano Y (2008) One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 115:141-146
13. Tano Y, Ophthalmic PDT Study Group (2008) Guidelines for PDT in Japan. Ophthalmology 115:585.e6-585.e6
14. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419-1431
15. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432-1444
16. Novack GD (2008) Pharmacotherapy for the treatment of choroidal neovascularization due to age-related macular degeneration. Annu Rev Pharmacol Toxicol 48:61-78
17. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145:239-248
18. Zarbin MA (2004) Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 122:598-614
19. Lazic R, Gabric N (2007) Intravitreally administered bevacizumab (Avastin) inminimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245:68-73
20. Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M, Tano Y (2008) Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 92:70-73
21. Lai TY, Chan WM, Liu DT, Luk FO, Lam DS (2008) Intravitreal bevacizumab (Avastin) with orwithout photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol 92:661-666
22. Gelisken F, Lafaut BA, Inhoffen W, Voelker M, Grisanti S, Bartz- Schmidt KU (2004) Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy. Br J Ophthalmol 88:207-211 (Pubitemid 38142088)
23. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO (2003) Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44:4473-4480
24. Spaide RF, Sorenson J, Maranan L (2005) Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112:301-304 (Pubitemid 40202568)
25. Weigert G, Michels S, Sacu S, Varga A, Prager F, Geitzenauer W, Schmidt-Erfurth U (2008) Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 92:356-360
26. Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W, Simpson JM (2005) Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 112:139-143
27. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN (2008) Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 145:249-256
28. Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group (2007) Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114:1868-1875
29. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, Kotlovker D, Chung CY, Kim RY, FOCUS Study Group (2006) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 124:1532-1542
30. Antoszyk AN, Tuomi L, Chung CY, Singh A, FOCUS Study Group (2008) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 145:862-874
31. Wolf S, PROTECT Study Group (2007) Nine month exploratory endpoint results from an open-label, multicenter, phase II study of same-day verteporfin and ranibizumab 0.5 mg (PROTECT Study), as measured using optical coherence tomography (OCT), fundus photography and fluorescein angiography (FA). Invest Ophthalmol Vis Sci 48:E-Abstract 2871
32. Smith BT, Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA (2008) Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina 28:675-681
33. Lazic R, Gabric N (2007) Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 114:1179-1185
34. Kaiser PK, Registry of Visudyne AMD Therapy Writing Committee 2009) Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 116:747-755
35. Visudyne in Minimally Classic Choroidal Neovascularization Study Group (2005) Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 123:448-457
36. Costagliola C, Romano MR, Rinaldi M, Dell'omo R, Chiosi F, Menzione M, Semeraro F (2009) Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age related macular degeneration. Br J Ophthalmol. doi:10.1136/ bjo.2009.159343